Neue Novavax: Anstieg nach 1:20 Re-Split

www.nasdaq.com/press-release/...omltfnd5Ydzg9ZvR-2rtzaHfdb16k

COVID-19 vaccine candidates

... He said they are working on manufacturing and distributing Novavax as well as an undisclosed vaccine candidate.

... “Our colleagues in North Carolina started manufacture back in early summer and they’ve done some initial runs there and they’ve now transferred the manufacturing process to us here in Texas and we have started manufacturing that product for Novavax,” said Farrell.

... Farrell wasn’t sure when local candidates like Novavax would get FDA approval.

”Once Novavax gets approval then we’ll be ready to ship material from here,” Farell said.

www.kbtx.com/2020/12/16/...YeSNViwKbl6QuyL2bJYzh1AUWswHeXhM_k

Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine

... The company will work with Medsafe, New Zealand’s regulatory agency, to obtain product approvals as needed. Given the urgency of timely approval and delivery of vaccine during the pandemic, the regulatory review process may leverage review by prioritized regulatory bodies such as the U.S. Food and Drug Administration, European Medicines Agency and/or Medicines and Healthcare products Regulatory Authority in the United Kingdom.



ir.novavax.com/news-releases/...d-RNosj2MNsX73-r6CJnCRPFlIUIU

up to 200 mln doses of Novavax COVID vaccine

finance.yahoo.com/news/...reliminary-talks-buy-110937113.html

Es wird endlich konkreter!

Ardern Announces New Zealand’s Largest-Ever Immunization Program

-Aims to vaccinate entire population against Covid-19 next year
-Government secures vaccines from AstraZeneca, Novavax

... The government has secured two additional vaccines from pharmaceutical companies AstraZeneca Plc and Novavax Inc, and will have enough for all five million New Zealanders, Ardern said Thursday in Wellington. If proven to be safe and effective, immunization will begin with border workers and essential staff in the second quarter of 2021 followed by the general population in the second half, she said. The vaccines will be free to the public.

“This will be New Zealand’s largest immunization roll out ever,” Ardern said in a statement. “Most countries are factoring the roll out to take all of 2021 and some of 2022 to complete due to its scale and complexity, also due to production and delivery timeframes.”

www.bloomberg.com/news/articles/...j-eN_cX_VUL2PBA9smboHzFHV8

Novavax will have the capacity for ‘two billion doses’ of COVID-19 vaccine globally: Novavax Board Member

finance.yahoo.com/video/...y-two-billion-doses-163037888.html

Draft landscape of COVID-19 candidate vaccines

www.who.int/publications/m/item/...hXtC3vLKuXfpgKm7tKJ-dDrFP4

Sollte Modernas Impfstoff spätestens Anfang Januar zugelassen werden, besteht kein Zweifel das der dritte zugelassene Impfstoff NVX-CoV2373 sein wird, imo!

Impfstoffpreise, Finanzierungen und Auftragsvolumen.

www.bbc.com/news/...gDF0aD2w_TqxCCTe1MBfApnkREhbbAvtxK9w98_64

im Sommer impfen können. Grund hierfür, es brauche genügend Impfstoff und einen, der nicht bei extrem hohen Temperaturen gelagert werden müsse.

www.aerztezeitung.de/Politik/...gen-Corona-impfen-415764.html

PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico

-PREVENT-19 will assess the efficacy, safety and immunogenicity of NVX-CoV2373 in the prevention of COVID-19

-Trial to enroll up to 30,000 volunteers across approximately 115 sites in the U.S. and Mexico

-Two-thirds of enrollees to receive active vaccine

ir.novavax.com/news-releases/...t-19-pivotal-phase-3-efficacy

Novavax Vaccine Will Probably Work on New Covid Strain: CEO

Dec.28 -- Novavax Inc. Chief Executive Officer Stan Erck discusses the phase 3 trial of the company's Covid-19 vaccine and says the data so far have been at or above the levels of Moderna Inc. and Pfizer Inc. He speaks with Bloomberg's Alix Steel on "Bloomberg Markets."

finance.yahoo.com/video/...obably-covid-strain-160129967.html

up in RTP as phase 3 clinical trials begin

...Meeson said that normally a clinical trial would be done with a small amount of product and "hopefully that trial would be successful." After that, he said, you'd start making lots of product to take out and treat people with.

...But they're hopeful this different process will allow them to have millions of doses ready to go out to the American people once the trial comes to a conclusion.

abc11.com/...kWmTM9WojIwmuTbDyfjmEwcTvGadGslyA0X1-bLqMLxivUjY

"Vaccines are very safe. We wouldn't be putting this into people or even testing at all if there was any hint it was not going to be safe." @Novavax president of R&D Dr. Gregory Glenn

twitter.com/joshchapinabc11/status/1343696518126194690?s=21

www.nytimes.com/interactive/2020/health/...dQtK9Qa6tEVytf6RSI

Novavax: The Moment Of Truth Arrives seekingalpha.com/article/4397145-moment-of-truth-for-novavax

Novavax can assess shot’s efficacy on new COVID-19 variant - Cantor Fitzgerald

Weighing in on the COVID-19 vaccine candidate from Novavax (NVAX +3.4%), Cantor Fitzgerald analyst Charles Duncan says the company has an opportunity to assess the shot's efficacy against the original strain and the newly-found U.K. variant.

In December, the U.K. notified the WHO on the new strain of COVID-19 thought to be highly transmissible than its predecessors.

“We believe the study has a high [probability of success] as it will be a composite efficacy endpoint against the two strains,” Barron’s quoted the analyst saying.

In November, Novavax announced that it completed the enrollment of 15,000 participants in a pivotal Phase 3 clinical trial for the vaccine candidate conducted in the U.K. with results expected in Q1 2021.

In December, the Phase 3 study for its COVID-19 vaccine candidate started in the U.S. and Mexico. Novavax’s vaccine candidate, NVX-CoV2373, is a protein-based jab engineered from the genetic sequence of SARS-CoV-2, the virus causing COVID-19.

Noting that the vaccine is not based on messenger RNA technology, but with a more established approach,’ the article says, ‘an effective Covid- 19 vaccine that works differently from the currently authorized vaccines could help relieve supply chain pressures, and get more people vaccinated faster.’

Duncan pegs a 60% probability for the vaccine to reach a 90% efficacy rate in line with those achieved by Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX). Such a result will drive shares up 30%, he predicts.

However, Novavax has already surged over 2,500% over the past 12-month period, but Wall Street remains cheery on the stock, with five ratings on the stock outnumbering two neutral or bearish recommendations.

Novavax can assess shot’s efficacy on new COVID-19 variant - Cantor Fitzgerald seekingalpha.com/news/...idminus-19-variant-cantor-fitzgerald

Deal mit Australien

www.n-tv.de/wirtschaft/der_boersen_tag/...rticle22279617.html

...ist für mich hier Schluss, man soll nicht zu gierig sein!

Aussichten sind auch nicht mehr so rosig!

Bin nun komplett raus.

Denke aber gerade jetzt wird es spannend, natürlich mit hohem Risiko.  

Link zum Video:

knect365.wistia.com/medias/...-UCz7aHVVprfbF589vwxnYnkk1Bed_Y

Investor Presentation January 2021
(J.P. MORGAN 39TH ANNUAL HEALTHCARE CONFERENCE - VIRTUAL)

www.novavax.com/sites/default/files/...DNMSVzV99s7UxPJX2DbMFE

Baxter Biopharma Solutions Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

-Agreement will help increase commercial production and promote access in United Kingdom and European markets

-Manufacturing to take place at Baxter’s state-of-the-art Halle/Westfalen, Germany facility

www.baxter.com/baxter-newsroom/...qBBiC3yVataczPSE3ld0_fwu0y8

Baxter-Werk in Halle produziert bald im Auftrag von Biontech – später auch für Novavax

Impfstoff aus OWL ab März

Halle (WB/dpa) - Der Pharmakonzern Baxter will in seinem Werk in Halle spätestens Anfang März mit der Auftragsfertigung des Corona-Impfstoffs von Biontech beginnen. Später soll auch für das US-Unternehmen Novavax ein Vakzin in OWL hergestellt werden.

www.westfalen-blatt.de/OWL/...avax-Impfstoff-aus-OWL-ab-Maerz

Serum Institute to stockpile Novavax vaccine candidate from around April

The Serum Institute of India, the world's biggest vaccine maker, will start stockpiling millions of doses of the Novavax coronavirus vaccine candidate starting around April, CEO Adar Poonawalla told the Reuters Next conference on Thursday.

"Upwards of 40-50 million doses per month is what we are trying to stockpile starting from April," he said.

www.hindustantimes.com/india-news/..._Ez8cjJv2j5k3ZVLsdEu7uEY